Top

Clinical Reviews in Allergy & Immunology

Published in:

Open Access 01-10-2017

Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity

Authors: Taher E. Taher, Jonas Bystrom, Voon H. Ong, David A. Isenberg, Yves Renaudineau, David J. Abraham, Rizgar A. Mageed

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2017

Abstract

B lymphocytes are critical for effective immunity; they produce antibodies and cytokines, present antigens to T lymphocytes and regulate immune responses. However, because of the inherent randomness in the process of generating their vast repertoire of antigen-specific receptors, B cells can also cause diseases through recognizing and reacting to self. Therefore, B lymphocyte selection and responses require tight regulation at multiple levels and at all stages of their development and activation to avoid diseases. Indeed, newly generated B lymphocytes undergo rigorous tolerance mechanisms in the bone marrow and, subsequently, in the periphery after their migration. Furthermore, activation of mature B cells is regulated through controlled expression of co-stimulatory receptors and intracellular signalling thresholds. All these regulatory events determine whether and how B lymphocytes respond to antigens, by undergoing apoptosis or proliferation. However, defects that alter regulated co-stimulatory receptor expression or intracellular signalling thresholds can lead to diseases. For example, autoimmune diseases can result from altered regulation of B cell responses leading to the emergence of high-affinity autoreactive B cells, autoantibody production and tissue damage. The exact cause(s) of defective B cell responses in autoimmune diseases remains unknown. However, there is evidence that defects or mutations in genes that encode individual intracellular signalling proteins lead to autoimmune diseases, thus confirming that defects in intracellular pathways mediate autoimmune diseases. This review provides a synopsis of current knowledge of signalling proteins and pathways that regulate B lymphocyte responses and how defects in these could promote autoimmune diseases. Most of the evidence comes from studies of mouse models of disease and from genetically engineered mice. Some, however, also come from studying B lymphocytes from patients and from genome-wide association studies. Defining proteins and signalling pathways that underpin atypical B cell response in diseases will help in understanding disease mechanisms and provide new therapeutic avenues for precision therapy.

Yu X (2015) Autoimmune diseases: what have we learned from mice? Curr Pharm Des 21(18):2306–2307. doi:10.1038/mp.2016.165 PubMedCrossRef

Konsta OD, Le Dantec C, Brooks WH, Renaudineau Y (2015) Genetics and epigenetics of autoimmune diseases. eLS 1–9; Brooks Wh, J Autoimmunity, 2010

Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, Stacker SA, Dunn AR (1995) Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 83(2):301–311PubMedCrossRef

Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA (2005) Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 52(12):3955–3965. doi:10.1002/art.21416 PubMedCrossRef

Mary C, Laporte C, Parzy D, Santiago ML, Stefani F, Lajaunias F, Parkhouse RM, O’Keefe TL, Neuberger MS, Izui S et al (2000) Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice. J Immunol 165(6):2987–2996PubMedCrossRef

Liossis SN, Solomou EE, Dimopoulos MA, Panayiotidis P, Mavrikakis MM, Sfikakis PP (2001) B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J Investig Med 49(2):157–165. doi:10.2310/6650.2001.34042 PubMedCrossRef

Alarcón-Riquelme ME, Ziegler JT, Molineros J, Howard TD, Moreno-Estrada A, Sánchez-Rodríguez E, Ainsworth HC, Ortiz-Tello P, Comeau ME, Rasmussen A et al (2016) Genome-wide association study in an Amerindian ancestry population reveals novel systemic lupus erythematosus risk loci and the role of European admixture. Arthritis Rheumatol 68(4):932–943. doi:10.1002/art.39504 PubMedPubMedCentralCrossRef

Dai X, James RG, Habib T, Singh S, Jackson S, Khim S, Moon RT, Liggitt D, Wolf-Yadlin A, Buckner JH et al (2013) A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J Clin Invest 123(5):2024–2036. doi:10.1172/JCI66963 PubMedPubMedCentralCrossRef

Miyagawa H, Yamai M, Sakaguchi D, Kiyohara C, Tsukamoto H, Kimoto Y, Nakamura T, Lee JH, Tsai CY, Chiang BL et al (2008) Association of polymorphisms in complement component C3 gene with susceptibility to systemic lupus erythematosus. Rheumatol 47(2):158–164. doi:10.1093/rheumatology/kem321 CrossRef

10.

Vang T, Miletic AV, Bottini N, Mustelin T (2007) Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity 40(6):453–461. doi:10.1080/08916930701464897 PubMedCrossRef

11.

Hermiston ML, Tan AL, Gupta VA, Majeti R, Weiss A (2005) The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity 23(6):635–647. doi:10.1016/j.immuni.2005.11.001 PubMedCrossRef

12.

Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA (2007) Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 56(1):291–302. doi:10.1002/art.22309 PubMedCrossRef

13.

Halcomb KE, Musuka S, Gutierrez T, Wright HL, Satterthwaite AB (2008) Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells. Mol Immunol 46(2):233–241. doi:10.1016/j.molimm.2008.08.278 PubMedPubMedCentralCrossRef

14.

Kil LP, de Bruijn MJ, van Nimwegen M, Corneth OB, van Hamburg JP, Dingjan GM, Thaiss F, Rimmelzwaan GF, Elewaut D, Delsing D et al (2012) Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 119(16):3744–3756. doi:10.1182/blood-2011-12-397919 PubMedCrossRef

15.

Maas A, Hendriks RW (2001) Role of Bruton’s tyrosine kinase in B cell development. Dev Immunol 8(3–4):171–181PubMedPubMedCentralCrossRef

16.

Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA et al (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 107(29):13075–13080. doi:10.1073/pnas.1004594107 PubMedPubMedCentralCrossRef

17.

O’Keefe TL, Williams GT, Batista FD, Neuberger MS (1999) Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 189(8):1307–1313PubMedPubMedCentralCrossRef

18.

O’Keefe TL, Williams GT, Davies SL, Neuberger MS (1996) Hyperresponsive B cells in CD22-deficient mice. Science 274(5288):798–801PubMedCrossRef

19.

Uckun FM, Goodman P, Ma H, Dibirdik I, Qazi S (2010) CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia. Proc Natl Acad Sci U S A 107(39):16852–16857. doi:10.1073/pnas.1007896107 PubMedPubMedCentralCrossRef

20.

Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S (2002) CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 109(11):1453–1462. doi:10.1172/JCI15078 PubMedPubMedCentralCrossRef

21.

Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K (2000) Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165(11):6635–6643PubMedCrossRef

22.

Kuroki K, Tsuchiya N, Tsao BP, Grossman JM, Fukazawa T, Hagiwara K, Kano H, Takazoe M, Iwata T, Hashimoto H et al (2002) Polymorphisms of human CD19 gene: possible association with susceptibility to systemic lupus erythematosus in Japanese. Genes Immun 3(Suppl 1):S21–S30. doi:10.1038/sj.gene.6363906 PubMedCrossRef

23.

Yoshizaki A (2016) B lymphocytes in systemic sclerosis: abnormalities and therapeutic targets. J Dermatol 43(1):39–45. doi:10.1111/1346-8138.13184 PubMedCrossRef

24.

Bolland S, Ravetch JV (2000) Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 13(2):277–285PubMedCrossRef

25.

Yuasa T, Kubo S, Yoshino T, Ujike A, Matsumura K, Ono M, Ravetch JV, Takai T (1999) Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med 189(1):187–194PubMedPubMedCentralCrossRef

26.

Mackay M, Stanevsky A, Wang T, Aranow C, Li M, Koenig S, Ravetch JV, Diamond B (2006) Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med 203(9):2157–2164. doi:10.1084/jem.20051503 PubMedPubMedCentralCrossRef

27.

Maxwell MJ, Duan M, Armes JE, Anderson GP, Tarlinton DM, Hibbs ML (2011) Genetic segregation of inflammatory lung disease and autoimmune disease severity in SHIP-1−/− mice. J Immunol 186(12):7164–7175. doi:10.4049/jimmunol.1004185 PubMedCrossRef

28.

Taher TE, Parikh K, Flores-Borja F, Mletzko S, Isenberg DA, Peppelenbosch MP, Mageed RA (2010) Protein phosphorylation and kinome profiling reveal altered regulation of multiple signaling pathways in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 62(8):2412–2423. doi:10.1002/art.27505 PubMedCrossRef

29.

Anzelon AN, Wu H, Rickert RC (2003) Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol 4(3):287–294. doi:10.1038/ni892 PubMedCrossRef

30.

Suzuki A, Kaisho T, Ohishi M, Tsukio-Yamaguchi M, Tsubata T, Koni PA, Sasaki T, Mak TW, Nakano T (2003) Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J Exp Med 197(5):657–667PubMedPubMedCentralCrossRef

31.

Wu XN, Ye YX, Niu JW, Li Y, Li X, You X, Chen H, Zhao LD, Zeng XF, Zhang FC et al (2014) Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus. Sci Transl Med 6(2446):246ra299. doi:10.1126/scitranslmed.3009131

32.

Medgyesi D, Hobeika E, Biesen R, Kollert F, Taddeo A, Voll RE, Hiepe F, Reth M (2014) The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity. J Exp Med 211(3):427–440. doi:10.1084/jem.20131196 PubMedPubMedCentralCrossRef

33.

Qian Y, Giltiay N, Xiao J, Wang Y, Tian J, Han S, Scott M, Carter R, Jorgensen TN, Li X (2008) Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjogren’s syndrome. Eur J Immunol 38(8):2219–2228. doi:10.1002/eji.200738113 PubMedPubMedCentralCrossRef

34.

Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E, Juneblad K, Apel M, McManus R, Ho P et al (2010) Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 42(11):996–999. doi:10.1038/ng.688 PubMedPubMedCentralCrossRef

35.

Perricone C, Ciccacci C, Ceccarelli F, Di Fusco D, Spinelli FR, Cipriano E, Novelli G, Valesini G, Conti F, Borgiani P (2013) TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development. Immunogenetics 65(10):703–709. doi:10.1007/s00251-013-0717-6 PubMedCrossRef

36.

Potter C, Eyre S, Cope A, Worthington J, Barton A (2007) Investigation of association between the TRAF family genes and RA susceptibility. Ann Rheum Dis 66(10):1322–1326. doi:10.1136/ard.2006.065706 PubMedPubMedCentralCrossRef

37.

Chu Y, Vahl JC, Kumar D, Heger K, Bertossi A, Wojtowicz E, Soberon V, Schenten D, Mack B, Reutelshofer M et al (2011) B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood 117(7):2227–2236. doi:10.1182/blood-2010-09-306019 PubMedCrossRef

38.

Hovelmeyer N, Reissig S, Xuan NT, Adams-Quack P, Lukas D, Nikolaev A, Schluter D, Waisman A (2011) A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur J Immunol 41(3):595–601. doi:10.1002/eji.201041313 PubMedCrossRef

39.

Tavares RM, Turer EE, Liu CL, Advincula R, Scapini P, Rhee L, Barrera J, Lowell CA, Utz PJ et al (2010) The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 33(2):181–191. doi:10.1016/j.immuni.2010.07.017 PubMedPubMedCentralCrossRef

40.

Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, Ortmann W, Shifrin N, Petri MA, Kamboh MI, Manzi S et al (2008) Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 40(9):1062–1064. doi:10.1038/ng.202 PubMedPubMedCentralCrossRef

41.

Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, Pe’er I, Burtt NP, Blumenstiel B, DeFelice M et al (2007) Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 39(12):1477–1482. doi:10.1038/ng.2007.27 PubMedPubMedCentralCrossRef

42.

Kitaura Y, Jang IK, Wang Y, Han YC, Inazu T, Cadera EJ, Schlissel M, Hardy RR, Gu H (2007) Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. Immunity 26(5):567–578. doi:10.1016/j.immuni.2007.03.015 PubMedPubMedCentralCrossRef

43.

Bergholdt R, Taxvig C, Eising S, Nerup J, Pociot F (2005) CBLB variants in type 1 diabetes and their genetic interaction with CTLA4. J Leukoc Biol 77(4):579–585. doi:10.1189/jlb.0904524 PubMedCrossRef

44.

Gomez-Martin D, Ibarra-Sanchez M, Romo-Tena J, Cruz-Ruiz J, Esparza-Lopez J, Galindo-Campos M, Diaz-Zamudio M, Alcocer-Varela J (2013) Casitas B lineage lymphoma b is a key regulator of peripheral tolerance in systemic lupus erythematosus. Arthritis Rheum 65(4):1032–1042. doi:10.1002/art.3783 PubMedCrossRef

45.

Recher M, Burns SO, de la Fuente MA, Volpi S, Dahlberg C, Walter JE, Moffitt K, Mathew D, Honke N, Lang PA et al (2012) B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood 119(12):2819–2828PubMedPubMedCentralCrossRef

46.

Schurman SH, Candotti F (2003) Autoimmunity in Wiskott-Aldrich syndrome. Curr Opin Rheumatol 15(4):446–453PubMedCrossRef

47.

Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner JH (2007) Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 179(7):4704–4710PubMedCrossRef

48.

Jacob CO, Eisenstein M, Dinauer MC, Ming W, Liu Q, John S, Quismorio FP Jr, Reiff A, Myones BL, Kaufman KM et al (2012) Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase. Proc Natl Acad Sci U S A 109(2):E59–E67. doi:10.1073/pnas.1113251108 PubMedCrossRef

49.

Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, Ortmann W, Kosoy R, Ferreira RC, Nordmark G et al (2009) A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 41(11):1228–1233. doi:10.1038/ng.468 PubMedPubMedCentralCrossRef

50.

Morris DL, Sheng Y, Zhang Y, Wang YF, Zhu Z, Tombleson P, Chen L, Cunninghame Graham DS, Bentham J, Roberts AL et al (2016) Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus. Nat Genet 48(8):940–946. doi:10.1038/ng.3603 PubMedPubMedCentralCrossRef

51.

Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD, Nath SK et al (2008) Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 40(2):204–210. doi:10.1038/ng.81 PubMedPubMedCentralCrossRef

52.

Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C, Catanese JJ, Xie G, Stahl EA, Chen R et al (2009) Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 41(12):1313–1318. doi:10.1038/ng.479 PubMedPubMedCentralCrossRef

53.

Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z, Xu JH, Cai ZM, Huang W, Zhao GP et al (2009) Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 41(11):1234–1237. doi:10.1038/ng.472 PubMedCrossRef

54.

Kozyrev SV, Abelson AK, Wojcik J, Zaghlool A, Linga Reddy MV, Sanchez E, Gunnarsson I, Svenungsson E, Sturfelt G, Jonsen A et al (2008) Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet 2008 40(2):211–216. doi:10.1038/ng.79

55.

Sawalha AH, Kaufman KM, Kelly JA, Adler AJ, Aberle T, Kilpatrick J, Wakeland EK, Li QZ, Wandstrat AE, Karp DR et al (2008) Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 67(4):458–461. doi:10.1136/ard.2007.075424 PubMedCrossRef

56.

Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira RC, Pant PV et al (2008) Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 358(9):900–909. doi:10.1056/NEJMoa0707865 PubMedCrossRef

57.

Castillejo-Lopez C, Delgado-Vega AM, Wojcik J, Kozyrev SV, Thavathiru E, Wu YY, Sanchez E, Pollmann D, Lopez-Egido JR, Fineschi S et al (2012) Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK. Ann Rheum Dis 71(1):136–142. doi:10.1136/annrheumdis-2011-200085 PubMedCrossRef

58.

Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, Burtt NP, Gianniny L, Korman BD, Padyukov L, Kurreeman FA et al (2008) Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 40(10):1216–1223. doi:10.1038/ng.233 PubMedPubMedCentralCrossRef

59.

Yang W, Shen N, Ye DQ, Liu Q, Zhang Y, Qian XX, Hirankarn N, Ying D, Pan HF, Mok CC et al (2010) Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet 6(2):e1000841. doi:10.1371/journal.pgen.1000841 PubMedPubMedCentralCrossRef

60.

Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, Kelly JA, Dozmorov MG, Miceli-Richard C, Bowman S et al (2013) Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren’s syndrome. Nat Genet 45(11):1284–1292. doi:10.1038/ng.2792 PubMedCrossRef

61.

Kobayashi T, Shimabukuro-Demoto S, Yoshida-Sugitani R, Furuyama-Tanaka K, Karyu H, Sugiura Y, Shimizu Y, Hosaka T, Goto M, Kato N et al (2014) The histidine transporter SLC15A4 coordinates mTOR-dependent inflammatory responses and pathogenic antibody production. Immunity 41(3):375–388. doi:10.1016/j.immuni.2014.08.011 PubMedCrossRef

62.

Yang J, Yang W, Hirankarn N, Ye DQ, Zhang Y, Pan HF, Mok CC, Chan TM, Wong RW, Mok MY et al (2011) ELF1 is associated with systemic lupus erythematosus in Asian populations. Hum Mol Genet 20(3):601–607. doi:10.1093/hmg/ddq474 PubMedCrossRef

63.

Manjarrez-Orduno N, Marasco E, Chung SA, Katz MS, Kiridly JF, Simpfendorfer KR, Freudenberg J, Ballard DH, Nashi E, Hopkins TJ et al (2012) CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation. Nat Genet 44(11):1227–1230. doi:10.1038/ng.2439 PubMedPubMedCentralCrossRef

64.

Ding C, Ma Y, Chen X, Liu M, Cai Y, Hu X, Xiang D, Nath S, Zhang HG, Ye H et al (2013) Integrin CD11b negatively regulates BCR signalling to maintain autoreactive B cell tolerance. Nat Commun 4:2813. doi:10.1038/ncomms3813 PubMed

65.

Lessard CJ, Adrianto I, Ice JA, Wiley GB, Kelly JA, Glenn SB, Adler AJ, Li H, Rasmussen A, Williams AH et al (2012) Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet 90(4):648–660. doi:10.1016/j.ajhg.2012.02.023 PubMedPubMedCentralCrossRef

66.

Sheng YJ, Gao JP, Li J, Han JW, Xu Q, Hu WL, Pan TM, Cheng YL, Yu ZY, Ni C et al (2011) Follow-up study identifies two novel susceptibility loci PRKCB and 8p11.21 for systemic lupus erythematosus. Rheumatology (Oxford) 50(4):682–688. doi:10.1093/rheumatology/keq313 CrossRef

67.

Lewis MJ, Vyse S, Shields AM, Boeltz S, Gordon PA, Spector TD, Lehner PJ, Walczak H, Vyse TJ (2015) UBE2L3 polymorphism amplifies NF-kappaB activation and promotes plasma cell development, linking linear ubiquitination to multiple autoimmune diseases. Am J Hum Genet 96(2):221–234. doi:10.1016/j.ajhg.2014.12.024 PubMedPubMedCentralCrossRef

68.

Kaufman KM, Zhao J, Kelly JA, Hughes T, Adler A, Sanchez E, Ojwang JO, Langefeld CD, Ziegler JT, Williams AH et al (2013) Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups. Ann Rheum Dis 72(3):437–444. doi:10.1136/annrheumdis-2012-201851 PubMedCrossRef

69.

He B, Santamaria R, Xu W, Cols M, Chen K, Puga I, Shan M, Xiong H, Bussel JB, Chiu A et al (2010) The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 11(9):836–845. doi:10.1038/ni.1914 PubMedPubMedCentralCrossRef

70.

Gregersen PK, Amos CI, Lee AT, Lu Y, Remmers EF, Kastner DL, Seldin MF, Criswell LA, Plenge RM, Holers VM et al (2009) REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet 41(7):820–823. doi:10.1038/ng.395 PubMedPubMedCentralCrossRef

71.

Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–2581. doi:10.1056/NEJMoa032534 PubMedCrossRef

72.

Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM et al (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361(22):2143–2152. doi:10.1056/NEJMoa0904452 PubMedCrossRef

73.

Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221–232. doi:10.1056/NEJMoa0909905 PubMedPubMedCentralCrossRef

74.

Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, HERMES Trial Group et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676–688. doi:10.1056/NEJMoa0706383 PubMedCrossRef

75.

Daoussis D, Andonopoulos AP (2011) Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: comment on the article by Yoo. Rheumatol Int 31(6):841–842. doi:10.1007/s00296-010-1485-3 PubMedCrossRef

76.

Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O, group ERs (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74(6):1188–1194. doi:10.1136/annrheumdis-2013-204522 PubMedCrossRef

77.

Devauchelle-Pensec V, Morvan J, Rat AC, Jousse-Joulin S, Pennec Y, Pers JO, Jamin C, Renaudineau Y, Quintin-Roué I, Cochener B et al (2011) Effects of rituximab therapy on quality of life in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol 29(1):6–12PubMed

78.

Jousse-Joulin S, Devauchelle-Pensec V, Morvan J, Guias B, Pennec Y, Pers JO, Daridon C, Jamin C, Renaudineau Y, Roué IQ et al (2007) Ultrasound assessment of salivary glands in patients with primary Sjögren’s syndrome treated with rituximab: quantitative and Doppler waveform analysis. Biologics 1(3):311–319PubMedPubMedCentral

79.

Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, Hutin P, Renaudineau Y, Dueymes M, Loisel S et al (2007) BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren’s syndrome. Arthritis Rheum 56(5):1464–1477. doi:10.1002/art.22603 PubMedCrossRef

80.

Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, Roudaut A, Jamin C, Renaudineau Y, Roué IQ et al (2007) Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 57(2):310–317. doi:10.1002/art.22536 PubMedCrossRef

81.

Taher TE, Muhammad HA, Bariller E, Flores-Borja F, Renaudineau Y, Isenberg DA, Mageed RA (2013) B-lymphocyte signalling abnormalities and lupus immunopathology. Int Rev Immunol 32(4):428–444. doi:10.3109/08830185.2013.788648 PubMedCrossRef

82.

Isenberg DA (2012) Rituximab—it was the best of times, it was the worst of times. Autoimmun Rev 11(11):790–791. doi:10.1016/j.autrev.2012.02.005 PubMedCrossRef

83.

Seret G, Le Meur Y, Renaudineau Y, Youinou P (2012) Mesangial cell-specific antibodies are central to the pathogenesis of lupus nephritis. Clin Dev Immunol 2012:579670. doi:10.1155/2012/579670 PubMedCrossRef

84.

Cancro MP (2009) Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol 9(9):657–661. doi:10.1038/nri2621 PubMedPubMedCentralCrossRef

85.

Cambier JC, Gauld SB, Merrell KT, Vilen BJ (2007) B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat Rev Immunol 7(8):633–643. doi:10.1038/nri2133 PubMedPubMedCentralCrossRef

86.

Hartley SB, Crosbie J, Brink R, Kantor AB, Basten A, Goodnow CC (1991) Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 353(6346):765–769. doi:10.1038/353765a0 PubMedCrossRef

87.

Nemazee D (2006) Receptor editing in lymphocyte development and central tolerance. Nat Rev Immunol 6(10):728–740. doi:10.1038/nri1939 PubMedCrossRef

88.

Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA, Kutok JL, Kearney JF, Otipoby KL, Rajewsky K (2009) PI3 kinase signals BCR-dependent mature B cell survival. Cell 139(3):573–586. doi:10.1016/j.cell.2009.08.041 PubMedPubMedCentralCrossRef

89.

Wang LD, Clark MR (2003) B-cell antigen-receptor signalling in lymphocyte development. Immunol 110(4):411–420CrossRef

90.

Mocsai A, Ruland J, Tybulewicz VL (2010) The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 10(6):387–402. doi:10.1038/nri2765 PubMedPubMedCentralCrossRef

91.

Koretzky GA, Abtahian F, Silverman MA (2006) SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond. Nat Rev Immunol 6(1):67–78. doi:10.1038/nri1750 PubMedCrossRef

92.

Kurosaki T, Hikida M (2009) Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev 228(1):132–148. doi:10.1111/j.1600-065X.2008.00748.x PubMedCrossRef

93.

Oellerich T, Bremes V, Neumann K, Bohnenberger H, Dittmann K, Hsiao HH, Engelke M, Schnyder T, Batista FD, Urlaub H et al (2011) The B-cell antigen receptor signals through a preformed transducer module of SLP65 and CIN85. EMBO J 30(17):3620–3634. doi:10.1038/emboj.2011.251 PubMedPubMedCentralCrossRef

94.

Oh-hora M, Rao A (2008) Calcium signaling in lymphocytes. Curr Opin Immunol 20(3):250–258. doi:10.1016/j.coi.2008.04.004 PubMedPubMedCentralCrossRef

95.

Gross AJ, Lyandres JR, Panigrahi AK, Prak ET, DeFranco AL (2009) Developmental acquisition of the Lyn-CD22-SHP-1 inhibitory pathway promotes B cell tolerance. J Immunol 182(9):5382–5392. doi:10.4049/jimmunol.0803941 PubMedPubMedCentralCrossRef

96.

Cornall RJ, Cyster JG, Hibbs ML, Dunn AR, Otipoby KL, Clark EA, Goodnow CC (1998) Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 8(4):497–508PubMedCrossRef

97.

Lamagna C, Hu Y, DeFranco AL, Lowell CA (2014) B cell-specific loss of Lyn kinase leads to autoimmunity. J Immunol 192(3):919–928. doi:10.4049/jimmunol.1301979 PubMedCrossRef

98.

Hua Z, Gross AJ, Lamagna C, Ramos-Hernandez N, Scapini P, Ji M, Shao H, Lowell CA, Hou B, DeFranco AL (2014) Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice. J Immunol 192(3):875–885. doi:10.4049/jimmunol.1300683 PubMedCrossRef

99.

Lu R, Vidal GS, Kelly JA, Delgado-Vega AM, Howard XK, Macwana SR, Dominguez N, Klein W, Burrell C, Harley IT et al (2009) Genetic associations of LYN with systemic lupus erythematosus. Genes Immun 10(5):397–403. doi:10.1038/gene.2009.19 PubMedPubMedCentralCrossRef

100.

Hermiston ML, Xu Z, Weiss A (2003) CD45: a critical regulator of signaling thresholds in immune cells. Ann Rev Immunol 21:107–137. doi:10.1146/annurev.immunol.21.120601.140946 CrossRef

101.

Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, Welstead G, Griffiths E, Krawczyk C, Richardson CD, Aitken K et al (2001) CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409(6818):349–354. doi:10.1038/35053086 PubMedCrossRef

102.

Roach T, Slater S, Koval M, White L, Cahir McFarland ED, Okumura M, Thomas M, Brown E (1997) CD45 regulates Src family member kinase activity associated with macrophage integrin-mediated adhesion. Curr Biol 7(6):408–417PubMedCrossRef

103.

Piercy J, Petrova S, Tchilian EZ, Beverley PC (2006) CD45 negatively regulates tumour necrosis factor and interleukin-6 production in dendritic cells. Immunology 118(2):250–256. doi:10.1111/j.1365-2567.2006.02363.x PubMedPubMedCentralCrossRef

104.

Gregori S, Mangia P, Bacchetta R, Tresoldi E, Kolbinger F, Traversari C, Carballido JM, de Vries JE, Korthauer U, Roncarolo MG (2005) An anti-CD45RO/RB monoclonal antibody modulates T cell responses via induction of apoptosis and generation of regulatory T cells. J Exp Med 201(8):1293–1305. doi:10.1084/jem.20040912 PubMedPubMedCentralCrossRef

105.

Brooks WP, Lynes MA (2001) Effects of hemizygous CD45 expression in the autoimmune Fasl(gld/gld) syndrome. Cell Immunol 212(1):24–34. doi:10.1006/cimm.2001.1845 PubMedCrossRef

106.

Greer SF, Justement LB (1999) CD45 regulates tyrosine phosphorylation of CD22 and its association with the protein tyrosine phosphatase SHP-1. J Immunol 162(9):5278–5286PubMed

107.

Benatar T, Carsetti R, Furlonger C, Kamalia N, Mak T, Paige CJ (1996) Immunoglobulin-mediated signal transduction in B cells from CD45-deficient mice. J Exp Med 183(1):329–334PubMedCrossRef

108.

Surolia I, Pirnie SP, Chellappa V, Taylor KN, Cariappa A, Moya J, Liu H, Bell DW, Driscoll DR, Diederichs S et al (2010) Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature 466(7303):243–247. doi:10.1038/nature09115 PubMedPubMedCentralCrossRef

109.

Cyster JG, Healy JI, Kishihara K, Mak TW, Thomas ML, Goodnow CC (1996) Regulation of B-lymphocyte negative and positive selection by tyrosine phosphatase CD45. Nature 381(6580):325–328. doi:10.1038/381325a0 PubMedCrossRef

110.

Aiba Y, Yamazaki T, Okada T, Gotoh K, Sanjo H, Ogata M, Kurosaki T (2006) BANK negatively regulates Akt activation and subsequent B cell responses. Immunity 24(3):259–268. doi:10.1016/j.immuni.2006.01.002 PubMedCrossRef

111.

Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM et al (2004) A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 75(2):330–337. doi:10.1086/422827 PubMedPubMedCentralCrossRef

112.

Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M et al (2004) A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 36(4):337–338. doi:10.1038/ng1323 PubMedCrossRef

113.

Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, Chang M, Ramos P, Baechler EC, Batliwalla FM et al (2004) Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 75(3):504–507. doi:10.1086/423790 PubMedPubMedCentralCrossRef

114.

Bootman MD (2012) Calcium signaling. Cold Spring Harb Perspect Biol 4(7):a011171. doi:10.1101/cshperspect.a011171 PubMedPubMedCentralCrossRef

115.

Matthews SA, Cantrell DA (2009) New insights into the regulation and function of serine/threonine kinases in T lymphocytes. Immunol Rev 228(1):241–252. doi:10.1111/j.1600-065X.2008.00759.x PubMedPubMedCentralCrossRef

116.

Im SH, Rao A (2004) Activation and deactivation of gene expression by Ca2+/calcineurin-NFAT-mediated signaling. Mol Cells 18(1):1–9PubMed

117.

Muller MR, Rao A (2010) NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol 10(9):645–656. doi:10.1038/nri2818 PubMedCrossRef

118.

Garaud S, Morva A, Lemoine S, Hillion S, Bordron A, Pers JO, Berthou C, Mageed RA, Renaudineau Y, Youinou P (2011) CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol 186(8):4835–4844. doi:10.4049/jimmunol.1003050 PubMedCrossRef

119.

Lyubchenko T, dal Porto J, Cambier JC, Holers VM (2005) Coligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway. J Immunol 174(6):3264–3272PubMedCrossRef

120.

Yarkoni Y, Getahun A, Cambier JC (2010) Molecular underpinning of B-cell anergy. Immunol Rev 237(1):249–263. doi:10.1111/j.1600-065X.2010.00936.x PubMedPubMedCentralCrossRef

121.

Gauld SB, Benschop RJ, Merrell KT, Cambier JC (2005) Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat Immunol 6(11):1160–1167. doi:10.1038/ni1256 PubMedCrossRef

122.

Bednarski JJ, Lyssiotis CA, Roush R, Boitano AE, Glick GD, Opipari AW Jr (2004) A novel benzodiazepine increases the sensitivity of B cells to receptor stimulation with synergistic effects on calcium signaling and apoptosis. J Biol Chem 279(28):29615–29621. doi:10.1074/jbc.M403507200 PubMedCrossRef

123.

Dhand R, Hara K, Hiles I, Bax B, Gout I, Panayotou G, Fry MJ, Yonezawa K, Kasuga M, Waterfield MD (1994) PI 3-kinase: structural and functional analysis of intersubunit interactions. EMBO J 13(3):511–521PubMedPubMedCentral

124.

Lehmann K, Muller JP, Schlott B, Skroblin P, Barz D, Norgauer J, Wetzker R (2009) PI3Kgamma controls oxidative bursts in neutrophils via interactions with PKCalpha and p47phox. Biochem J 419(3):603–610. doi:10.1042/BJ20081268 PubMedCrossRef

125.

Geering B, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B (2007) Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A 104(19):7809–7814. doi:10.1073/pnas.0700373104 PubMedPubMedCentralCrossRef

126.

Pirola L, Zvelebil MJ, Bulgarelli-Leva G, Van Obberghen E, Waterfield MD, Wymann MP (2001) Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling. J Biol Chem 276(24):21544–21554. doi:10.1074/jbc.M011330200 PubMedCrossRef

127.

Dyson JM, Fedele CG, Davies EM, Becanovic J, Mitchell CA (2012) Phosphoinositide phosphatases: just as important as the kinases. Subcell Biochem 58:215–279. doi:10.1007/978-94-007-3012-0_7 PubMedCrossRef

128.

Finlay D, Cantrell D (2011) The coordination of T-cell function by serine/threonine kinases. Cold Spring Harb Perspect Biol 3(1):a002261. doi:10.1101/cshperspect.a002261 PubMedPubMedCentralCrossRef

129.

Laplante M, Sabatini DM (2012) mTOR signaling. Cold Spring Harb Perspect Biol 4(2). doi:10.1101/cshperspect.a011593

130.

Kuo TC, Schlissel MS (2009) Mechanisms controlling expression of the RAG locus during lymphocyte development. Curr Opin Immunol 21(2):173–178. doi:10.1016/j.coi.2009.03.008 PubMedPubMedCentralCrossRef

131.

Hart GT, Wang X, Hogquist KA, Jameson SC (2011) Kruppel-like factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and trafficking molecule expression. Proc Natl Acad Sci U S A 108(2):716–721. doi:10.1073/pnas.1013168108 PubMedCrossRef

132.

Bi L, Okabe I, Bernard DJ, Nussbaum RL (2002) Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 13(3):169–172. doi:10.1007/s00335-001-2123-x PubMed

133.

Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C, Vanhaesebroeck B (2006) Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 107(2):642–650. doi:10.1182/blood-2005-07-3041 PubMedCrossRef

134.

Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A, Humphries LA, Rawlings D, Reynolds H, Vigorito E et al (2002) A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 196(6):753–763PubMedPubMedCentralCrossRef

135.

Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L, Sozzani S, Mantovani A, Altruda F, Wymann MP (2000) Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287(5455):1049–1053PubMedCrossRef

136.

Jou ST, Carpino N, Takahashi Y, Piekorz R, Chao JR, Carpino N, Wang D, Ihle JN (2002) Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 22(24):8580–8591PubMedPubMedCentralCrossRef

137.

Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B, Wakeham A, Itie A, Bouchard D, Kozieradzki I et al (2000) Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287(5455):1040–1046PubMedCrossRef

138.

Barber DF, Bartolome A, Hernandez C, Flores JM, Fernandez-Arias C, Rodriguez-Borlado L, Hirsch E, Wymann M, Balomenos D, Carrera AC (2006) Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion. J Immunol 176(1):589–593PubMedCrossRef

139.

Barber DF, Bartolome A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C, Camps M, Ruckle T, Schwarz MK, Rodriguez S et al (2005) PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 11(9):933–935. doi:10.1038/nm1291 PubMed

140.

Maxwell MJ, Tsantikos E, Kong AM, Vanhaesebroeck B, Tarlinton DM, Hibbs ML (2012) Attenuation of phosphoinositide 3-kinase delta signaling restrains autoimmune disease. J Autoimmun 38(4):381–391. doi:10.1016/j.jaut.2012.04.001 PubMedCrossRef

141.

Suarez-Fueyo A, Barber DF, Martinez-Ara J, Zea-Mendoza AC, Carrera AC (2011) Enhanced phosphoinositide 3-kinase delta activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death. J Immunol 187(5):2376–2385. doi:10.4049/jimmunol.1101602 PubMedCrossRef

142.

Omori SA, Cato MH, Anzelon-Mills A, Puri KD, Shapiro-Shelef M, Calame K, Rickert RC (2006) Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity 25(4):545–557. doi:10.1016/j.immuni.2006.08.015 PubMedCrossRef

143.

Omori SA, Rickert RC (2007) Phosphatidylinositol 3-kinase (PI3K) signaling and regulation of the antibody response. Cell Cycle 6(4):397–402. doi:10.4161/cc.6.4.3837 PubMedCrossRef

144.

Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, Waterfield MD et al (2002) Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297(5583):1031–1034. doi:10.1126/science.1073560 PubMed

145.

Durand CA, Hartvigsen K, Fogelstrand L, Kim S, Iritani S, Vanhaesebroeck B, Witztum JL, Puri KD, Gold MR (2009) Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol 183(9):5673–5684. doi:10.4049/jimmunol.0900432 PubMedCrossRef

146.

Beer-Hammer S, Zebedin E, von Holleben M, Alferink J, Reis B, Dresing P, Degrandi D, Scheu S, Hirsch E, Sexl V et al (2010) The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation. J Leukoc Biol 87(6):1083–1095. doi:10.1189/jlb.0809585 PubMedCrossRef

147.

Dil N, Marshall AJ (2009) Role of phosphoinositide 3-kinase p110 delta in TLR4- and TLR9-mediated B cell cytokine production and differentiation. Mol Immunol 46(10):1970–1978. doi:10.1016/j.molimm.2009.03.010 PubMedCrossRef

148.

Marone R, Cmiljanovic V, Giese B, Wymann MP (2008) Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 1784(1):159–185. doi:10.1016/j.bbapap.2007.10.003 PubMedCrossRef

149.

Rommel C, Camps M, Ji H (2007) PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 7(3):191–201. doi:10.1038/nri2036 PubMedCrossRef

150.

Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B et al (2005) Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11(9):936–943. doi:10.1038/nm1284 PubMed

151.

Gonzalez-Martin A, Adams BD, Lai M, Shepherd J, Salvador-Bernaldez M, Salvador JM, Lu J, Nemazee D, Xiao C (2016) The microRNA miR-148a functions as a critical regulator of B cell tolerance and autoimmunity. Nat Immunol 17(4):433–440. doi:10.1038/ni.3385 PubMedPubMedCentralCrossRef

152.

Getahun A, Beavers NA, Larson SR, Shlomchik MJ, Cambier JC (2016) Continuous inhibitory signaling by both SHP-1 and SHIP-1 pathways is required to maintain unresponsiveness of anergic B cells. J Exp Med 213(5):751–769. doi:10.1084/jem.20150537 PubMedPubMedCentralCrossRef

153.

Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425–479. doi:10.1146/annurev.biochem.67.1.425 PubMedCrossRef

154.

Chen J, Chen ZJ (2013) Regulation of NF-kappaB by ubiquitination. Curr Opin Immunol 25(1):4–12. doi:10.1016/j.coi.2012.12.005 PubMedPubMedCentralCrossRef

155.

Haglund K, Di Fiore PP, Dikic I (2003) Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem Sci 28(11):598–603. doi:10.1016/j.tibs.2003.09.005 PubMedCrossRef

156.

Hitotsumatsu O, Ahmad RC, Tavares R, Wang M, Philpott D, Turer EE, Lee BL, Shiffin N, Advincula R, Malynn BA et al (2008) The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 28(3):381–390. doi:10.1016/j.immuni.2008.02.002 PubMedPubMedCentralCrossRef

157.

Duan L, Reddi AL, Ghosh A, Dimri M, Band H (2004) The Cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling. Immunity 21(1):7–17. doi:10.1016/j.immuni.2004.06.012 PubMedCrossRef

158.

Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, Mariathasan S, Bouchard D, Wakeham A, Itie A et al (2000) Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403(6766):211–216. doi:10.1038/35003228 PubMedCrossRef

159.

Keane MM, Rivero-Lezcano OM, Mitchell JA, Robbins KC, Lipkowitz S (1995) Cloning and characterization of cbl-b: a SH3 binding protein with homology to the c-cbl proto-oncogene. Oncogene 10(12):2367–2377PubMed

160.

Lupher ML Jr, Rao N, Eck MJ, Band H (1999) The Cbl protooncoprotein: a negative regulator of immune receptor signal transduction. Immunol Today 20(8):375–382PubMedCrossRef

161.

Ota Y, Beitz LO, Scharenberg AM, Donovan JA, Kinet JP, Samelson LE (1996) Characterization of Cbl tyrosine phosphorylation and a Cbl-Syk complex in RBL-2H3 cells. J Exp Med 184(5):1713–1723PubMedCrossRef

162.

Yasuda T, Maeda A, Kurosaki M, Tezuka T, Hironaka K, Yamamoto T, Kurosaki T (2000) Cbl suppresses B cell receptor-mediated phospholipase C (PLC)-gamma2 activation by regulating B cell linker protein-PLC-gamma2 binding. J Exp Med 191(4):641–650PubMedPubMedCentralCrossRef

163.

Yasuda T, Tezuka T, Maeda A, Inazu T, Yamanashi Y, Gu H, Kurosaki T, Yamamoto T (2002) Cbl-b positively regulates Btk-mediated activation of phospholipase C-gamma2 in B cells. J Exp Med 196(1):51–63PubMedPubMedCentralCrossRef

164.

Rao N, Dodge I, Band H (2002) The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J Leukoc Biol 71(5):753–763PubMed

165.

Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC (1999) The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286(5438):309–312PubMedCrossRef

166.

Drake L, McGovern-Brindisi EM, Drake JR (2006) BCR ubiquitination controls BCR-mediated antigen processing and presentation. Blood 108(13):4086–4093. doi:10.1182/blood-2006-05-025338 PubMedPubMedCentralCrossRef

167.

Katkere B, Rosa S, Caballero A, Repasky EA, Drake JR (2010) Physiological-range temperature changes modulate cognate antigen processing and presentation mediated by lipid raft-restricted ubiquitinated B cell receptor molecules. J Immunol 185(9):5032–5039. doi:10.4049/jimmunol.1001653 PubMedCrossRef

168.

Katkere B, Rosa S, Drake JR (2012) The Syk-binding ubiquitin ligase c-Cbl mediates signaling-dependent B cell receptor ubiquitination and B cell receptor-mediated antigen processing and presentation. J Biol Chem 287(20):16636–16644. doi:10.1074/jbc.M112.357640 PubMedPubMedCentralCrossRef

169.

Zhang M, Veselits M, O’Neill S, Hou P, Reddi AL, Berlin I, Ikeda M, Nash PD, Longnecker R, Band H et al (2007) Ubiquitinylation of Ig beta dictates the endocytic fate of the B cell antigen receptor. J Immunol 179(7):4435–4443PubMedCrossRef

170.

Veselits M, Tanaka A, Lipkowitz S, O’Neill S, Sciammas R, Finnegan A, Zhang J, Clark MR (2014) Recruitment of Cbl-b to B cell antigen receptor couples antigen recognition to Toll-like receptor 9 activation in late endosomes. PLoS One 9(3):e89792. doi:10.1371/journal.pone.0089792 PubMedPubMedCentralCrossRef

171.

Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu O et al (2004) The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 5(10):1052–1060. doi:10.1038/ni1110 PubMedCrossRef

172.

Heyninck K, De Valck D, Vanden Berghe W, Van Criekinge W, Contreras R, Fiers W, Haegeman G, Beyaert R (1999) The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN. J Cell Biol 145(7):1471–1482PubMedPubMedCentralCrossRef

173.

Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, Ma A (2000) Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289(5488):2350–2354PubMedPubMedCentralCrossRef

174.

Shembade N, Ma A, Harhaj EW (2010) Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 327(5969):1135–1139. doi:10.1126/science.1182364 PubMedPubMedCentralCrossRef

175.

Beyaert R, Heyninck K, Van Huffel S (2000) A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol 60(8):1143–1151PubMedCrossRef

176.

Bosanac I, Wertz IE, Pan B, Yu C, Kusam S, Lam C, Phu L, Phung Q, Maurer B, Arnott D, Kirkpatrick DS et al (2010) Ubiquitin binding to A20 ZnF4 is required for modulation of NF-kappaB signaling. Mol Cell 40(4):548–557. doi:10.1016/j.molcel.2010.10.009 PubMedCrossRef

177.

Lu TT, Onizawa M, Hammer GE, Turer EE, Yin Q, Damko E, Agelidis A, Shifrin N, Advincula R, Barrera J et al (2013) Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity 38(5):896–905. doi:10.1016/j.immuni.2013.03.008 PubMedPubMedCentralCrossRef

178.

Skaug B, Chen J, Du F, He J, Ma A, Chen ZJ (2011) Direct, noncatalytic mechanism of IKK inhibition by A20. Mol Cell 44(4):559–571. doi:10.1016/j.molcel.2011.09.015 PubMedPubMedCentralCrossRef

179.

Tokunaga F, Nishimasu H, Ishitani R, Goto E, Noguchi T, Mio K, Kamei K, Ma A, Iwai K, Nureki O (2012) Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-kappaB regulation. EMBO J 31(19):3856–3870. doi:10.1038/emboj.2012.241 PubMedPubMedCentralCrossRef

180.

Verhelst K, Carpentier I, Kreike M, Meloni L, Verstrepen L, Kensche T, Dikic I, Beyaert R (2012) A20 inhibits LUBAC-mediated NF-kappaB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J 31(19):3845–3855. doi:10.1038/emboj.2012.240 PubMedPubMedCentralCrossRef

181.

Lin SC, Chung JY, Lamothe B, Rajashankar K, Lu M, Lo YC, Lam AY, Darnay BG, Wu H (2008) Molecular basis for the unique deubiquitinating activity of the NF-kappaB inhibitor A20. J Mol Biol 376(2):526–540. doi:10.1016/j.jmb.2007.11.092 PubMedCrossRef

182.

Wertz IE, O’Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL et al (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430(7000):694–699. doi:10.1038/nature02794 PubMedCrossRef

183.

Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, Jang IK, Gutkind JS, Shevach E, Gu H (2000) Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403:216(6766)–216(67220. doi:10.1038/35003235

184.

Rudd CE, Schneider H (2000) Lymphocyte signaling: Cbl sets the threshold for autoimmunity. Curr Biol 10(9):R344–R347PubMedCrossRef

185.

Vereecke L, Beyaert R, van Loo G (2009) The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 30(8):383–391. doi:10.1016/j.it.2009.05.007 PubMedCrossRef

186.

Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon JM, Burtt NP, Guiducci C, Parkin M, Gates C et al (2008) Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 40(9):1059–1061. doi:10.1038/ng.200 PubMedPubMedCentralCrossRef

187.

Hughes LB, Reynolds RJ, Brown EE, Kelley JM, Thomson B, Conn DL, Jonas BL, Westfall AO, Padilla MA, Callahan LF et al (2010) Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. Arthritis Rheum 62(12):3547–3553. doi:10.1002/art.27732 PubMedPubMedCentralCrossRef

188.

Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ et al (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41(2):199–204. doi:10.1038/ng.311 PubMedPubMedCentralCrossRef

189.

Eyre S, Hinks A, Bowes J, Flynn E, Martin P, Wilson AG, Morgan AW, Emery P, Steer S, Hocking LJ, Early Arthritis Consortium et al (2010) Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Res Ther 12(5):R175. doi:10.1186/ar3139 PubMedPubMedCentralCrossRef

190.

Fung EY, Smyth DJ, Howson JM, Cooper JD, Walker NM, Stevens H, Wicker LS, Todd JA (2009) Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun 10(2):188–191. doi:10.1038/gene.2008.99 PubMedCrossRef

191.

Dieude P, Guedj M, Wipff J, Ruiz B, Riemekasten G, Matucci-Cerinic M, Melchers I, Hachulla E, Airo P, Diot E et al (2010) Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis 69(11):1958–1964. doi:10.1136/ard.2009.127928 PubMedCrossRef

192.

Koumakis E, Giraud M, Dieude P, Cohignac V, Cuomo G, Airo P, Hachulla E, Matucci-Cerinic M, Diot E, Caramaschi P et al (2012) Brief report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity. Arthritis Rheum 64(8):2746–2752. doi:10.1002/art.34490 PubMedCrossRef

193.

Adrianto I, Wen F, Templeton A, Wiley G, King JB, Lessard CJ, Bates JS, Hu Y, Kelly JA, Kaufman KM et al (2011) Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet 43(3):253–258. doi:10.1038/ng.766 PubMedPubMedCentralCrossRef

194.

Boonyasrisawat W, Eberle D, Bacci S, Zhang YY, Nolan D, Gervino EV, Johnstone MT, Trischitta V, Shoelson SE, Doria A (2007) Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes 56(2):499–505. doi:10.2337/db06-0946 PubMedCrossRef

195.

Elsby LM, Orozco G, Denton J, Worthington J, Ray DW, Donn RP (2010) Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis. Clin Exp Rheumatol 28(5):708–714PubMedPubMedCentral

196.

Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, Kekow J, Thiesen HJ (2008) Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 10(3):R50. doi:10.1186/ar2419 PubMedPubMedCentralCrossRef

197.

Nocturne G, Tarn J, Boudaoud S, Locke J, Miceli-Richard C, Hachulla E, Dubost JJ, Bowman S, Gottenberg JE, Criswell LA et al (2016) Germline variation of TNFAIP3 in primary Sjögren’s syndrome-associated lymphoma. Ann Rheum Dis 75(4):780–783. doi:10.1136/annrheumdis-2015-207731 PubMedCrossRef

198.

Orozco G, Eyre S, Hinks A, Bowes J, Morgan AW, Wilson AG, Wordsworth P, Steer S, Hocking L, Consortium U et al (2011) Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 70(3):463–468. doi:10.1136/ard.2010.137174 PubMedCrossRef

199.

Wang S, Adrianto I, Wiley GB, Lessard CJ, Kelly JA, Adler AJ, Glenn SB, Williams AH, Ziegler JT, Comeau ME et al (2012) A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus. Genes Immun 13(5):380–387. doi:10.1038/gene.2012.6 PubMedPubMedCentralCrossRef

200.

Lewis M, Vyse S, Shields A, Boeltz S, Gordon P, Spector T, Lehner P, Walczak H, Vyse T (2015) Effect of UBE2L3 genotype on regulation of the linear ubiquitin chain assembly complex in systemic lupus erythematosus. Lancet 385(Suppl 1):S9. doi:10.1016/S0140-6736(15)60324-5 PubMedCrossRef

201.

Browne EP (2012) Regulation of B-cell responses by Toll-like receptors. Immunology 136(4):370–379. doi:10.1111/j.1365-2567.2012.03587.x PubMedPubMedCentralCrossRef

202.

Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y, Saitoh T, Kawai T, Takeuchi O, Akira S (2008) Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol 9(6):684–691. doi:10.1038/ni.160 PubMedCrossRef

203.

Negishi H, Fujita Y, Yanai H, Sakaguchi S, Ouyang X, Shinohara M, Takayanagi H, Ohba Y, Taniguchi T, Honda K (2006) Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program. Proc Natl Acad Sci U S A 103(41):15136–15141. doi:10.1073/pnas.0607181103 PubMedPubMedCentralCrossRef

204.

Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM, Fitzgerald KA, Golenbock DT (2005) The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem 280(17):17005–17012. doi:10.1074/jbc.M412584200 PubMedCrossRef

205.

Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, Kano S, Honda K, Ohba Y, Mak TW et al (2005) Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434(7030):243–249. doi:10.1038/nature03308 PubMedCrossRef

206.

Jackson SW, Kolhatkar NS, Rawlings DJ (2015) B cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody production. Curr Opin Immunol 33:70–77. doi:10.1016/j.coi.2015.01.018 PubMedPubMedCentralCrossRef

207.

Suurmond J, Diamond B (2015) Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest 125(6):2194–2202. doi:10.1172/JCI78084 PubMedPubMedCentralCrossRef

208.

Chaturvedi A, Dorward D, Pierce SK (2008) The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity 28(6):799–809. doi:10.1016/j.immuni.2008.03.019 PubMedPubMedCentralCrossRef

209.

Chaturvedi A, Pierce SK (2009) How location governs toll-like receptor signaling. Traffic 10(6):621–628. doi:10.1111/j.1600-0854.2009.00899.x PubMedPubMedCentralCrossRef

210.

Berland R, Fernandez L, Kari E, Han JH, Lomakin I, Akira S, Wortis HH, Kearney JF, Ucci AA, Imanishi-Kari T (2006) Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity 25(3):429–440. doi:10.1016/j.immuni.2006.07.014 PubMedCrossRef

211.

Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ (2005) Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 202(2):321–331. doi:10.1084/jem.20050338 PubMedPubMedCentralCrossRef

212.

Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ (2006) Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25(3):417–428. doi:10.1016/j.immuni.2006.07.013 PubMedCrossRef

213.

Lartigue A, Courville P, Auquit I, Francois A, Arnoult C, Tron F, Gilbert D, Musette P (2006) Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. J Immunol 177(2):1349–1354PubMedCrossRef

214.

Jackson SW, Scharping NE, Kolhatkar NS, Khim S, Schwartz MA, Li QZ, Hudkins KL, Alpers CE, Liggitt D, Rawlings DJ (2014) Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation. J Immunol 192(10):4525–4532. doi:10.4049/jimmunol.1400098 PubMedPubMedCentralCrossRef

215.

Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA (1994) A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 125(6 Pt 1):876–885PubMedCrossRef

216.

Becker-Herman S, Meyer-Bahlburg A, Schwartz MA, Jackson SW, Hudkins KL, Liu C, Sather BD, Khim S, Liggitt D, Song W et al (2011) WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J Exp Med 208(10):2033–2042. doi:10.1084/jem.20110200 PubMedPubMedCentralCrossRef

217.

Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV (2006) TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 203(3):553–561PubMedPubMedCentralCrossRef

218.

Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, Sweet MJ, Smyth MJ, Mackay CR, Mackay F (2007) BAFF and MyD88 signals promote a lupus like disease independent of T cells. J Exp Med 204(8):1959–1971. doi:10.1084/jem.20062567 PubMedPubMedCentralCrossRef

219.

Teichmann LL, Schenten D, Medzhitov R, Kashgarian M, Shlomchik MJ (2013) Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. Immunity 38(3):528–540. doi:10.1016/j.immuni.2012.11.017 PubMedPubMedCentralCrossRef

220.

Deane JA, Pisitkun P, Barrett RS, Feigenbaum L, Town T, Ward JM, Flavell RA, Bolland S (2007) Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 27(5):801–810. doi:10.1016/j.immuni.2007.09.009 PubMedPubMedCentralCrossRef

221.

Walsh ER, Pisitkun P, Voynova E, Deane JA, Scott BL, Caspi RR, Bolland S (2012) Dual signaling by innate and adaptive immune receptors is required for TLR7-induced B-cell-mediated autoimmunity. Proc Natl Acad Sci U S A 109(40):16276–16281. doi:10.1073/pnas.1209372109 PubMedPubMedCentralCrossRef

222.

Sun X, Wiedeman A, Agrawal N, Teal TH, Tanaka L, Hudkins KL, Alpers CE, Bolland S, Buechler MB, Hamerman JA et al (2013) Increased ribonuclease expression reduces inflammation and prolongs survival in TLR7 transgenic mice. J Immunol 190(6):2536–2543. doi:10.4049/jimmunol.1202689 PubMedPubMedCentralCrossRef

223.

Garcia-Ortiz H, Velazquez-Cruz R, Espinosa-Rosales F, Jimenez-Morales S, Baca V, Orozco L (2010) Association of TLR7 copy number variation with susceptibility to childhood-onset systemic lupus erythematosus in Mexican population. Ann Rheum Dis 69(10):1861–1865. doi:10.1136/ard.2009.124313 PubMedCrossRef

224.

Kawasaki A, Furukawa H, Kondo Y, Ito S, Hayashi T, Kusaoi M, Matsumoto I, Tohma S, Takasaki Y, Hashimoto H et al (2011) TLR7 single-nucleotide polymorphisms in the 3′ untranslated region and intron 2 independently contribute to systemic lupus erythematosus in Japanese women: a case-control association study. Arthritis Res Ther 13(2):R41. doi:10.1186/ar3277 PubMedPubMedCentralCrossRef

225.

Shen N, Fu Q, Deng Y, Qian X, Zhao J, Kaufman KM, Wu YL, Yu CY, Tang Y, Chen JY et al (2010) Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci U S A 107(36):15838–15843. doi:10.1073/pnas.1001337107 PubMedPubMedCentralCrossRef

226.

Konsta OD, Le Dantec C, Charras A, Brooks WH, Arleevskaya MI, Bordron A, Renaudineau Y (2015) An in silico approach reveals associations between genetic and epigenetic factors within regulatory elements in B cells from primary Sjögren’s syndrome patients. Front Immunol 6:437. doi:10.3389/fimmu.2015.00437 PubMedPubMedCentralCrossRef

227.

Desnues B, Macedo AB, Roussel-Queval A, Bonnardel J, Henri S, Demaria O, Alexopoulou L (2014) TLR8 on dendritic cells and TLR9 on B cells restrain TLR7-mediated spontaneous autoimmunity in C57BL/6 mice. Proc Natl Acad Sci U S A 111(4):1497–1502. doi:10.1073/pnas.1314121111 PubMedPubMedCentralCrossRef

228.

Isnardi I, Ng YS, Srdanovic I, Motaghedi R, Rudchenko S, von Bernuth H, Zhang SY, Puel A, Jouanguy E, Picard C et al (2008) IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 29(5):746–757. doi:10.1016/j.immuni.2008.09.015 PubMedPubMedCentralCrossRef

229.

Kurosaki T, Shinohara H, Baba Y (2010) B cell signaling and fate decision. Annu Rev Immunol 28:21–55. doi:10.1146/annurev.immunol.021908.132541 PubMedCrossRef

230.

Mageed RA, Garaud S, Taher TE, Parikh K, Pers JO, Jamin C, Renaudineau Y, Youinou P (2012) CD5 expression promotes multiple intracellular signaling pathways in B lymphocyte. Autoimmun Rev 11(11):795–798. doi:10.1016/j.autrev.2012.02.007 PubMedCrossRef

231.

Renaudineau Y, Hillion S, Saraux A, Mageed RA, Youinou P (2005) An alternative exon 1 of the CD5 gene regulates CD5 expression in human B lymphocytes. Blood 106(8):2781–2789. doi:10.1182/blood-2005-02-0597 PubMedCrossRef

232.

Youinou P, Renaudineau Y (2007) The paradox of CD5-expressing B cells in systemic lupus erythematosus. Autoimmun Rev 7(2):149–154. doi:10.1016/j.autrev.2007.02.016 PubMedCrossRef

233.

Daeron M, Lesourne R (2006) Negative signaling in Fc receptor complexes. Adv Immunol 89:39–86. doi:10.1016/S0065-2776(05)89002-9 PubMedCrossRef

234.

Parry RV, Harris SJ, Ward SG (2010) Fine tuning T lymphocytes: a role for the lipid phosphatase SHIP-1. Biochim Biophys Acta 1804(3):592–597. doi:10.1016/j.bbapap.2009.09.019 PubMedCrossRef

235.

Séïté JF, Cornec D, Renaudineau Y, Youinou P, Mageed RA, Hillion S (2010) IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood 116(10):1698–1704. doi:10.1182/blood-2009-12-261461 PubMedCrossRef

236.

Kumanogoh A, Watanabe C, Lee I, Wang X, Shi W, Araki H, Hirata H, Iwahori K, Uchida J, Yasui T et al (2000) Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity 13(5):621–631PubMedCrossRef

237.

Wu Y, Nadler MJ, Brennan LA, Gish GD, Timms JF, Fusaki N, Jongstra-Bilen J, Tada N, Pawson T, Wither J et al (1998) The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1. Curr Biol 8(18):1009–1017PubMedCrossRef

238.

Li DH, Tung JW, Tarner IH, Snow AL, Yukinari T, Ngernmaneepothong R, Martinez OM, Parnes JR (2006) CD72 down-modulates BCR-induced signal transduction and diminishes survival in primary mature B lymphocytes. J Immunol 176(9):5321–5328PubMedCrossRef

239.

Shi W, Kumanogoh A, Watanabe C, Uchida J, Wang X, Yasui T, Yukawa K, Ikawa M, Okabe M, Parnes JR et al (2000) The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. Immunity 13(5):633–642PubMedCrossRef

240.

Early GS, Zhao W, Burns CM (1996) Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 157(7):3159–3164PubMed

241.

Ma J, Xu J, Madaio MP, Peng Q, Zhang J, Grewal IS, Flavell RA, Craft J (1996) Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses. J Immunol 157(2):417–426PubMed

242.

Wang X, Huang W, Schiffer LE, Mihara M, Akkerman A, Hiromatsu K, Davidson A (2003) Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 48(2):495–506. doi:10.1002/art.10929 PubMedCrossRef

243.

Kyburz D, Corr M, Brinson DC, Von Damm A, Tighe H, Carson DA (1999) Human rheumatoid factor production is dependent on CD40 signaling and autoantigen. J Immunol 163(6):3116–3122PubMed

244.

Tellander AC, Michaelsson E, Brunmark C, Andersson M (2000) Potent adjuvant effect by anti-CD40 in collagen-induced arthritis. Enhanced disease is accompanied by increased production of collagen type-II reactive IgG2a and IFN-gamma. J Autoimmun 14(4):295–302. doi:10.1006/jaut.2000.0374 PubMedCrossRef

245.

Baker RL, Wagner DH Jr, Haskins K (2008) CD40 on NOD CD4 T cells contributes to their activation and pathogenicity. J Autoimmun 31(4):385–392. doi:10.1016/j.jaut.2008.09.001 PubMedCrossRef

246.

Balasa B, Krahl T, Patstone G, Lee J, Tisch R, McDevitt HO, Sarvetnick N (1997) CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 159(9):4620–4627PubMed

247.

Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, Bluestone JA (2004) Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest 114(7):979–987. doi:10.1172/JCI20483 PubMedPubMedCentralCrossRef

248.

Green EA, Wong FS, Eshima K, Mora C, Flavell RA (2000) Neonatal tumor necrosis factor alpha promotes diabetes in nonobese diabetic mice by CD154-independent antigen presentation to CD8(+) T cells. J Exp Med 191(2):225–238PubMedPubMedCentralCrossRef

249.

Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, Claassen E (1996) CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 93(6):2499–2504PubMedPubMedCentralCrossRef

250.

Howard LM, Miga AJ, Vanderlugt CL, Dal Canto MC, Laman JD, Noelle RJ, Miller SD (1999) Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest 103(2):281–290. doi:10.1172/JCI5388 PubMedPubMedCentralCrossRef

251.

Boon L, Brok HP, Bauer J, Ortiz-Buijsse A, Schellekens MM, Ramdien-Murli S, Blezer E, van Meurs M, Ceuppens J, de Boer M et al (2001) Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J Immunol 167(5):2942–2949PubMedCrossRef

252.

Boon L, Laman JD, Ortiz-Buijsse A, den Hartog MT, Hoffenberg S, Liu P, Shiau F, de Boer M (2002) Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology 174(1):53–65PubMedCrossRef

253.

Laman JD, t Hart BA, Brok H, Meurs M, Schellekens MM, Kasran A, Boon L, Bauer J, Boer M, Ceuppens J (2002) Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12). Eur J Immunol 32(8):2218–2228. doi:10.1002/1521-4141(200208)32:8<2218::AID-IMMU2218>3.0.CO;2-0 PubMedCrossRef

254.

Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A, Group BGLNT (2003) A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48(3):719–727. doi:10.1002/art.10856 PubMedCrossRef

255.

Ford ML, Adams AB, Pearson TC (2004) Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol 10(1):14–24. doi:10.1038/nrneph.2013.183 CrossRef

256.

Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D, Group I-LS (2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(12):3251–3258. doi:10.1002/art.10681 PubMedCrossRef

257.

Zouali M, Sarmay G (2004) B lymphocyte signaling pathways in systemic autoimmunity: implications for pathogenesis and treatment. Arthritis Rheum 50(9):2730–2741. doi:10.1002/art.20487 PubMedCrossRef

258.

Jiang Y, Hirose S, Sanokawa-Akakura R, Abe M, Mi X, Li N, Miura Y, Shirai J, Zhang D, Hamano Y, Shirai T (1999) Genetically determined aberrant down-regulation of FcgammaRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus. Int Immunol 11(10):1685–1691PubMedCrossRef

259.

Li DH, Winslow MM, Cao TM, Chen AH, Davis CR, Mellins ED, Utz PJ, Crabtree GR, Parnes JR (2008) Modulation of peripheral B cell tolerance by CD72 in a murine model. Arthritis Rheum 58(10):3192–3204. doi:10.1002/art.23812 PubMedPubMedCentralCrossRef

260.

Healy JI, Dolmetsch RE, Timmerman LA, Cyster JG, Thomas ML, Crabtree GR, Lewis RS, Goodnow CC (1997) Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity 6(4):419–428PubMedCrossRef

261.

Dolmetsch RE, Lewis RS, Goodnow CC, Healy JI (1997) Differential activation of transcription factors induced by Ca2+ response amplitude and duration. Nature 386(6627):855–858. doi:10.1038/386855a0 PubMedCrossRef

262.

Chiles TC (2004) Regulation and function of cyclin D2 in B lymphocyte subsets. J Immunol 173(5):2901–2907PubMedCrossRef

263.

Winslow MM, Gallo EM, Neilson JR, Crabtree GR (2006) The calcineurin phosphatase complex modulates immunogenic B cell responses. Immunity 24(2):141–152. doi:10.1016/j.immuni.2005.12.013 PubMedCrossRef

264.

Ghoreschi K, Laurence A, O’Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228(1):273–287. doi:10.1111/j.1600-065X.2008.00754.x PubMedPubMedCentralCrossRef

265.

Harrison DA (2012) The Jak/STAT pathway. Cold Spring Harb Perspect Biol 4(3). doi:10.1101/cshperspect.a011205

266.

Cantrell DA (2003) GTPases and T cell activation. Immunol Rev 192:122–130PubMedCrossRef

267.

Okkenhaug K, Fruman DA (2010) PI3Ks in lymphocyte signaling and development. Curr Top Microbiol Immunol 346:57–85. doi:10.1007/82_2010_45 PubMedPubMedCentral

268.

O’Shea JJ, Paul WE (2010) Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 327(5969):1098–1102. doi:10.1126/science.1178334 PubMedPubMedCentralCrossRef

269.

Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, Browning JL, Mackay F (2000) BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 192(10):1453–1466PubMedPubMedCentralCrossRef

270.

Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, Scott ML (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293(5537):2111–2114. doi:10.1126/science.1061964 PubMedCrossRef

271.

Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A (2000) Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 10(13):785–788PubMedCrossRef

272.

Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C et al (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293(5537):2108–2111. doi:10.1126/science.1061965 PubMedCrossRef

273.

Fairfax KA, Tsantikos E, Figgett WA, Vincent FB, Quah PS, LePage M, Hibbs ML, Mackay F (2015) BAFF-driven autoimmunity requires CD19 expression. J Autoimmun 62:1–10. doi:10.1016/j.jaut.2015.06.001 PubMedCrossRef

274.

Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ (2009) Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229(1):152–172. doi:10.1111/j.1600-065X.2009.00782.x PubMedCrossRef

275.

Rickert RC, Jellusova J, Miletic AV (2011) Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev 244(1):115–133. doi:10.1111/j.1600-065X.2011.01067.x PubMedPubMedCentralCrossRef

276.

Brightbill HD, Jackman JK, Suto E, Kennedy H, Jones C 3rd, Chalasani S, Lin Z, Tam L, Roose-Girma M, Balazs M et al (2015) Conditional deletion of NF-kappaB-inducing kinase (NIK) in adult mice disrupts mature B cell survival and activation. J Immunol 195(3):953–964. doi:10.4049/jimmunol.1401514 PubMedCrossRef

277.

Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9(7):491–502. doi:10.1038/nri2572 PubMedCrossRef

278.

Otipoby KL, Sasaki Y, Schmidt-Supprian M, Patke A, Gareus R, Pasparakis M, Tarakhovsky A, Rajewsky K (2008) BAFF activates Akt and Erk through BAFF-R in an IKK1-dependent manner in primary mouse B cells. Proc Natl Acad Sci U S A 105(34):12435–12438. doi:10.1073/pnas.0805460105 PubMedPubMedCentralCrossRef

279.

Hobeika E, Levit-Zerdoun E, Anastasopoulou V, Pohlmeyer R, Altmeier S, Alsadeq A, Dobenecker MW, Pelanda R, Reth M (2015) CD19 and BAFF-R can signal to promote B-cell survival in the absence of Syk. EMBO J 34(7):925–939. doi:10.15252/embj.201489732 PubMedPubMedCentralCrossRef

280.

Schweighoffer E, Vanes L, Nys J, Cantrell D, McCleary S, Smithers N, Tybulewicz VL (2013) The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway. Immunity 38(3):475–488. doi:10.1016/j.immuni.2012.11.015 PubMedPubMedCentralCrossRef

281.

Lund FE (2008) Cytokine-producing B lymphocytes—key regulators of immunity. Curr Opin Immunol 20(3):332–338. doi:10.1016/j.coi.2008.03.003 PubMedPubMedCentralCrossRef

282.

Dang VD, Hilgenberg E, Ries S, Shen P, Fillatreau S (2014) From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsets. Curr Opin Immunol 28:77–83. doi:10.1016/j.coi.2014.02.009 PubMedCrossRef

283.

Shen P, Roch T, Lampropoulou V, O’Connor RA, Stervbo U, Hilgenberg E, Ries S, Dang VD, Jaimes Y, Daridon C et al (2014) IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507(7492):366–370. doi:10.1038/nature12979 PubMedPubMedCentralCrossRef

284.

Sweet RA, Lee SK, Vinuesa CG (2012) Developing connections amongst key cytokines and dysregulated germinal centers in autoimmunity. Curr Opin Immunol 24(6):658–664. doi:10.1016/j.coi.2012.10.003 PubMedCrossRef

285.

Blenman KR, Duan B, Xu Z, Wan S, Atkinson MA, Flotte TR, Croker BP, Morel L (2006) IL-10 regulation of lupus in the NZM2410 murine model. Lab Investig 86(11):1136–1148. doi:10.1038/labinvest.3700468 PubMed

286.

Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L, Alarcon-Segovia D, Wijdenes J et al (2000) Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43(8):1790–1800. doi:10.1002/1529-0131(200008)43:8<1790::AID-ANR15>3.0.CO;2-2 PubMedCrossRef

287.

Watanabe R, Ishiura N, Nakashima H, Kuwano Y, Okochi H, Tamaki K, Sato S, Tedder TF, Fujimoto M (2010) Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol 184(9):4801–4809. doi:10.4049/jimmunol.0902385 PubMedPubMedCentralCrossRef

288.

Capper ER, Maskill JK, Gordon C, Blakemore AI (2004) Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology? Clin Exp Immunol 138(2):348–356. doi:10.1111/j.1365-2249.2004.02607.x PubMedPubMedCentralCrossRef

289.

Braun D, Caramalho I, Demengeot J (2002) IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol 14(4):411–419PubMedCrossRef

290.

Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, Gonzalez Escribano MF et al (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38(5):550–555. doi:10.1038/ng1782 PubMedCrossRef

291.

Ronnblom L, Eloranta ML, Alm GV (2006) The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 54(2):408–420. doi:10.1002/art.21571 PubMedCrossRef

292.

Nguyen KB, Watford WT, Salomon R, Hofmann SR, Pien GC, Morinobu A, Gadina M, O’Shea JJ, Biron CA (2002) Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 297(5589):2063–2066. doi:10.1126/science.1074900 PubMedCrossRef

293.

Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielinski CC, Smolen JS (1991) Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Rheumatol 18(10):1621–1622PubMed

294.

Jackson SW, Jacobs HM, Arkatkar T, Dam EM, Scharping NE, Kolhatkar NS, Hou B, Buckner JH, Rawlings DJ (2016) B cell IFN-gamma receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. J Exp Med 213(5):733–750. doi:10.1084/jem.20151724 PubMedPubMedCentralCrossRef

295.

Ettinger R, Kuchen S, Lipsky PE (2008) Interleukin 21 as a target of intervention in autoimmune disease. Ann Rheum Dis 67(Suppl 3):iii83–iii86. doi:10.1136/ard.2008.098400 PubMedCrossRef

296.

Moisini I, Davidson A (2009) BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol 158(2):155–163. doi:10.1111/j.1365-2249.2009.04007.x PubMedPubMedCentralCrossRef

297.

Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190(11):1697–1710PubMedPubMedCentralCrossRef

298.

Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, Cyster JG (2004) Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20(4):441–453PubMedCrossRef

299.

Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, Brink R (2004) Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20(6):785–798. doi:10.1016/j.immuni.2004.05.010 PubMedCrossRef

300.

Haapaniemi EM, Kaustio M, Rajala HL, van Adrichem AJ, Kainulainen L, Glumoff V, Doffinger R, Kuusanmaki H, Heiskanen-Kosma T, Trotta L et al (2015) Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood 125(4):639–648. doi:10.1182/blood-2014-04-570101 PubMedPubMedCentralCrossRef

301.

Kotkowska A, Sewerynek E, Domańska D, Pastuszak-Lewandoska D, Brzeziańska E (2015) Single nucleotide polymorphisms in the STAT3 gene influence AITD susceptibility, thyroid autoantibody levels, and IL6 and IL17 secretion. Cell Mol Biol Lett 20(1):88–101. doi:10.1515/cmble-2015-0004 PubMedCrossRef

302.

Nakayamada S, Kubo S, Iwata S, Tanaka Y (2016) Chemical JAK inhibitors for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. doi:10.1080/14656566.2016.1241237 PubMed

303.

Deng GM, Kyttaris VC, Tsokos GC (2016) Targeting Syk in autoimmune rheumatic diseases. Front Immunol 7(7):78–82. doi:10.3389/fimmu.2016.00078 PubMedPubMedCentral

304.

Schwartz DM, Bonelli M, Gadina M, O’Shea JJ (2016) Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12(1):25–36. doi:10.1038/nrrheum.2015.167 PubMedCrossRef

305.

Lazaro E, Scherlinger M, Truchetet ME, Chiche L, Schaeverbeke T, Blanco P, Richez C (2016) Biotherapies in systemic lupus erythematosus: new targets. Joint Bone Spine 20(16):30123–30133. doi:10.1016/j.jbspin.2016.07.004

306.

Lazzerini PE, Capecchi PL, Guidelli GM, Selvi E, Acampa M, Laghi-Pasini F (2016) Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date. Drug Des Devel Ther 26(10):3083–3098CrossRef

307.

Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, Dimonaco S, Mitchell N (2016) Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis 75(6):1081–1091. doi:10.1136/annrheumdis-2015-207628 PubMedCrossRef

308.

Oon S, Wilson NJ, Wicks I (2016) Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunology 5(5):e79. doi:10.1038/cti.2016.26 PubMedPubMedCentralCrossRef

309.

Achek A, Yesudhas D, Choi S (2016) Toll-like receptors: promising therapeutic targets for inflammatory diseases. Ach Pharm Res 39(8):1032–1049. doi:10.1007/s12272-016-0806-9 CrossRef

310.

Chalmers SA, Doerner J, Bosanac T, Khalil S, Smith D, Harcken C, Dimock J, Der E, Herlitz L, Webb D et al (2016) Therapeutic blockade of immune complex-mediated glomerulonephritis by highly selective inhibition of Bruton’s tyrosine kinase. Sci Rep 6:26164. doi:10.1038/srep26164 PubMedPubMedCentralCrossRef

311.

Park JK, Byun JY, Park JA, Kim YY, Lee YJ, Oh JI, Jang SY, Kim YH, Song YW, Son J et al (2015) HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis. Arthritis Res Ther 18:91. doi:10.1186/s13075-016-0988-z CrossRef

Title: Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity
Authors: Taher E. Taher
Jonas Bystrom
Voon H. Ong
David A. Isenberg
Yves Renaudineau
David J. Abraham
Rizgar A. Mageed
Publication date: 01-10-2017
Publisher: Springer US
Published in: Clinical Reviews in Allergy & Immunology / Issue 2/2017
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-017-8609-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Dysregulated Lymphoid Cell Populations in Mouse Models of Systemic Lupus Erythematosus

Immunophenotyping As a New Tool for Classification and Monitoring of Systemic Autoimmune Diseases

Could Lymphocyte Profiling be Useful to Diagnose Systemic Autoimmune Diseases?

Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?

Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF+ T Lymphocytes

Calcium Signaling: From Normal B Cell Development to Tolerance Breakdown and Autoimmunity.

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage